Gilead Sciences (Nasdaq: GILD ) reported earnings on Feb. 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Gilead Sciences met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share grew.
Margins contracted across the board.
Gilead Sciences reported revenue of $2.20 billion. The 22 analysts polled by S&P Capital IQ anticipated revenue of $2.18 billion. Sales were 10% higher than the prior-year quarter's $2.00 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.97. The 25 earnings estimates compiled by S&P Capital IQ forecast $1.04 per share on the same basis. GAAP EPS of $0.87 for Q4 were 14% higher than the prior-year quarter's $0.76 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 73.4%, 180 basis points worse than the prior-year quarter. Operating margin was 39.4%, 960 basis points worse than the prior-year quarter. Net margin was 30.2%, 130 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $2.22 billion. On the bottom line, the average EPS estimate is $1.00.
Next year's average estimate for revenue is $9.09 billion. The average EPS estimate is $4.13.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,105 members out of 2,164 rating the stock outperform, and 60 members rating it underperform. Among 621 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 612 give Gilead Sciences a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Gilead Sciences is outperform, with an average price target of $49.29.
The biotechnology and healthcare investing landscape is littered with also-rans and a few major winners. Is Gilead Sciences the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Gilead Sciences to My Watchlist.